Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1384&sort=-keywords
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-keywords", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1442&sort=-keywords", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1385&sort=-keywords", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1383&sort=-keywords" }, "data": [ { "type": "Grant", "id": "8904", "attributes": { "award_id": "1U18FD007519-01", "title": "Increasing the diagnostic PCR and next-generation sequencing capacity for the diagnosis and variant detection of COVID-19 in animals at the North Dakota State University Veterinary Diagnostic Lab", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24456, "first_name": "Olgica", "last_name": "Ceric", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-15", "end_date": "2022-09-30", "award_amount": 59941, "principal_investigator": { "id": 24728, "first_name": "Brianna", "last_name": "Stenger", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1775, "ror": "https://ror.org/05h1bnb22", "name": "North Dakota State University", "address": "", "city": "", "state": "ND", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1775, "ror": "https://ror.org/05h1bnb22", "name": "North Dakota State University", "address": "", "city": "", "state": "ND", "zip": "", "country": "United States", "approved": true }, "abstract": "The primary goal of this project is to increase the capacity for next-generation sequencing (NGS) and SARS-CoV-2 variant detection for the diagnosis of COVID-19 in animals by validating commercially available reagent kits for extraction, PCR, and NGS using a dedicated one-way NGS workflow. This will add the NDSU-VDL to the network of veterinary diagnostic laboratories capable and proficient at testing and sequencing SARS-CoV- 2 in samples from animals. To build this capacity, reagents and dedicated equipment for a one- way workflow are needed. There are three specific aims. 1) Validate the Applied Biosystems™ COVID-19 TaqPath™ Combo Kit for the detection of SARS-CoV-2 and diagnosis of COVID-19 in animal samples. Targeted samples include tissue homogenates and swabs (nasal, oral, fecal) from animals. Extracted product can be used for downstream next generation sequencing on long or short read platforms, such as the MinION or iSeq, respectively. 2) Create a safe, one- way workflow for next generation sequencing that will minimize contamination and increase sequencing capacity by allowing multiple technicians to work on different steps in the process at the same time. 3) Diagnose SARS-CoV-2 variants through next generation sequencing on the MinION platform. This will be accomplished using the NEBNext® ARTIC SARS-CoV-2 Companion Kit and protocol for the MinION for NGS and following the EPI2ME analysis pipeline. The use of the flongle flow cells will be evaluated to reduce sequencing costs. In addition, the amount of time, cost, and ease of use of this NGS library prep kit and analysis pipline will the compared with other laboratories evaluating different kits.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8909", "attributes": { "award_id": "1R01HS027985-01A1", "title": "Impact of COVID-19 on Drug Shortages", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24731, "first_name": "Meghan", "last_name": "Wagner", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-16", "end_date": "2026-08-31", "award_amount": 400000, "principal_investigator": { "id": 24732, "first_name": "KJ", "last_name": "Suda", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [ { "id": 848, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 848, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "Half of all US persons use at least 1 prescription drug; 24% use 3 or more. However, few of the drugs Ameri- cans take as a cornerstone to prevent and treat disease are produced domestically; the majority of medica- tions consumed in the US are produced in foreign facilities. Thus, the drug supply chain is global and suscep- tible to disruption due to unanticipated events, such as the 2019 Coronavirus pandemic (COVID-19). Unantic- ipated events may lead to drug shortages and treatment disruption. Treatment disruption has been associ- ated with worsening illness, increased hospitalization, and death. However, little is known on the frequency of drug shortages causing treatment disruption and subsequent impact on adverse clinical outcomes. This is especially true in long-term care and outpatient settings, where the majority of drug shortages occur. The US and Canada are both at risk for supply chain disruption leading to drug shortages in a global emergency. Dur- ing the pandemic, both countries implemented policies in an attempt to lessen the impact of drug shortages. However, Canadian policy was generally more stringent and implemented earlier. These policies may impact the drug supply chain differently allowing for comparison of policy effectiveness. Although the problem of drug shortages is well known, there is a gap in our knowledge of the impact of drug shortages during a global emergency. This gap is significant because drug shortages are occurring with increasing frequency and pop- ulation-based research is needed to inform future drug shortage strategy (e.g, domestic drug production). Guided by preliminary data, we will be pursuing 3 specific aims: 1) Determine how the pandemic impacted the drug supply chain leading to drug shortages in the US and Canada; [2) Assess drug shortages leading to treatment disruption in the US and Canada;] and 3) Determine the association between drug shortages and serious adverse clinical outcomes. The proposed study is aligned with the research priority areas of AHRQ (safer health care; improvements in health care practice), the Food and Drug Administration, and US legisla- tion. We will also assess the impact of drug shortages in AHRQ priority groups (minorities, uninsured, rural, inner-city, elderly, women, persons with multiple chronic conditions). We propose to conduct a population- based study to assess the impact of drug shortages and identify patient-, community-, supply chain- and drug-characteristics associated with drug shortages. [The expected outcomes of this study include timely evidence on the impact of drug shortages during a pandemic, including negative health outcomes, particularly among the most vulnerable populations. By comparing shortages in the US and Canada, we will identify the effectiveness of new U.S. legislation and emergency Canadian policy. An expert panel of key stakeholders will aid in dissemination and identify recommendations on effective shortage policies based on our results. The long-term goal is to plan for future global emergencies, drug shortages at large, and inform national- and international-policy to decrease the impact of drug shortages on patient outcomes.]", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8915", "attributes": { "award_id": "1U01CK000630-01", "title": "CK21-003, Oregon Child Absenteeism due to Respiratory Disease Study - 3", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2021-09-01", "end_date": "2024-08-31", "award_amount": 967373, "principal_investigator": { "id": 24738, "first_name": "JONATHAN L", "last_name": "TEMTE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 799, "ror": "", "name": "UNIVERSITY OF WISCONSIN-MADISON", "address": "", "city": "", "state": "WI", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 799, "ror": "", "name": "UNIVERSITY OF WISCONSIN-MADISON", "address": "", "city": "", "state": "WI", "zip": "", "country": "United States", "approved": true }, "abstract": "SUMMARY/ABSTRACT Background: Influenza (Flu) is common in children and a leading cause of school absenteeism. SARS-CoV-2 (SARS) has emerged as a significant pathogen, but the role of children in post-peak and post-pandemic transmission needs to be defined. Both viruses cause substantial morbidity, mortality and economic costs. As Flu is efficiently spread within school settings, rates of absenteeism have been proposed as an early warning system. Accordingly, we created and tested a simple modification of an existing electronic school information system (ESIS) to automatically report cause-specific absenteeism. We found a significant association between cause-specific K-12 school absenteeism and prevalence of medically-attended Flu in our six-year study, allowing for Flu monitoring and early warning for acceleration in community activity. We have also documented substantial within-household Flu transmission. Similar studies— using our established and effective methods—are needed for the newly emerged coronavirus, SARS. Program Goal: The goals of ORCHARDS-3 are to expand the absenteeism system to evaluate the effectiveness for SARS monitoring and to describe the level of within-household transmission of Flu and SARS from index cases who are school-aged children. Methods: We will use parental reporting of symptoms into a telephonic absence reporting system and an algorithm within the ESIS for daily absenteeism assessment. We will actively recruit ≥300 children absent due to Flu-like illness (ILI) or COVID-like illness (CLI) from the Oregon School District, Dane County, WI, in each of three years. Home visits will be used to collect detailed demographic, household, epidemiologic and symptom data, and nasal and NP/OP specimens for testing. Nasal specimens will be tested for Flu/SARS using SOFIA-2 FIA rapid testing. NP/OP specimens will be transported to the Wisconsin State Laboratory of Hygiene for Flu/SARS rRT-PCR testing and for the presence of other respiratory viruses using a Luminex Multiplex PCR platform. We will recruit ≥240 households/yr with ill children for transmission assessment. All household members will self-collect nasal specimens on day 0, 7 and 14 for Flu/SARS rRT-PCR and provide detailed illness data. Temporal patterns of absenteeism due to ILI and CLI will be compared to virological surveillance within the surrounding community. Rates of within-home transmission of Flu and SARS will be calculated. Significance: Transmission and amplification within schools, followed by transmission from children to other household members likely expands outbreaks. Cause-specific absenteeism monitoring of Flu and SARS may provide early detection in a community allowing for use of countermeasures.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8920", "attributes": { "award_id": "1F31HL160141-01", "title": "Elucidating the roles of CMPK2 in mitochondrial homeostasis and antiviral immunity", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 22653, "first_name": "EMMANUEL FRANCK", "last_name": "Mongodin", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-01", "end_date": "2024-08-31", "award_amount": 37043, "principal_investigator": { "id": 24747, "first_name": "Sylvia", "last_name": "Torres-Odio", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1643, "ror": "", "name": "TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1643, "ror": "", "name": "TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "Cytidine/uridine monophosphate kinase 2 (CMPK2) is an interferon-regulated enzyme that was originally reported to catalyze the ATP-dependent phosphorylation of dCMP and dUMP to diphosphate forms in vitro. Due to a putative mitochondrial targeting sequence, CMPK2 was postulated to function in the mitochondrial deoxyribonucleotide salvage pathway necessary for the synthesis and maintenance of mitochondrial DNA (mtDNA). However, more recent data have revealed that CMPK2 prefers ribonucleotide diphosphate substrates in vitro and functions to restrict HIV and other RNA viruses in cell based assays. Beyond these seemingly contrasting findings, no other studies have addressed the cellular localization and tissue expression patterns of CMPK2 or utilized genetic knockouts to determine true biological activity. Therefore, the overall objective of this proposal is to close these knowledge gaps and mechanistically advance understanding of CMPK2 in mitochondrial function, tissue homeostasis, and antiviral innate immunity using a diverse toolkit of cell and animal models. The central hypothesis is that by maintaining mitochondrial homeostasis, CMPK2 boosts cell-intrinsic innate immunity and limits runaway inflammation triggered by mitochondrial stressors and viral infection. In support of this hypothesis, ongoing studies have revealed that CMPK2 localizes strongly to mitochondria and that ectopic overexpression of CMPK2 is sufficient to protect cells from RNA virus infection. Moreover, after systemic challenge with innate immune agonists, CMPK2 is markedly upregulated in the lungs and liver, and CMPK2 knockout mice exhibit elevated expression of proinflammatory cytokines and type I interferon (IFN-I) responses after Toll-like receptor (TLR) stimulation. To gain additional insight into how CMPK2 functions in mitochondria and antiviral immunity, two related, but independent aims are proposed. Aim 1 will elucidate the molecular mechanisms by which CMPK2 maintains mitochondrial homeostasis at rest and during stress. Here, CMPK2 knockout cells, novel lines reconstituted with mutant CMPK2 vectors lacking nucleotide kinase activity or mitochondrial targeting, and whole body CMPK2 knockout mice will be utilized. Aim 2 will determine that the mitochondrial activity of CMPK2 restricts coronavirus replication and maintains mitochondrial function during infection. Here, an intranasal mouse hepatitis virus challenge protocol that models acute respiratory distress syndrome and closely mirrors coronavirus pneumonia in humans will be employed. This research will fundamentally advance our understanding of how CMPK2 functions in mitochondrial homeostasis and antiviral innate immunity at both the cellular and organismal levels. Moreover, it may have a positive impact on public health by revealing novel CMPK2-centered strategies to maintain mitochondrial homeostasis, boost antiviral immunity, and limit damaging inflammation during coronavirus infection.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8927", "attributes": { "award_id": "1R01HS028404-01", "title": "Developing improved guidelines for nursing home-associated viral respiratory infections: Learning from the COVID-19 experience", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24670, "first_name": "Leyi", "last_name": "Lin", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-01", "end_date": "2025-08-31", "award_amount": 493096, "principal_investigator": { "id": 24752, "first_name": "LORI Lea", "last_name": "POPEJOY", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1049, "ror": "", "name": "UNIVERSITY OF MISSOURI-COLUMBIA", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 24753, "first_name": "Amy Ann", "last_name": "Vogelsmeier", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1049, "ror": "", "name": "UNIVERSITY OF MISSOURI-COLUMBIA", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true }, "abstract": "The COVID-19 pandemic highlighted the vulnerability of the nearly 1.4 million nursing home (NH) residents to respiratory healthcare associated infections (HAI) such as COVID-19. By August 2020, there were nearly 200,000 confirmed cases of COVID-19 with more than 50,000 reported resident deaths. NH residents are vulnerable to respiratory HAI because of multiple comorbidities and physical and cognitive frailty. These vulnerabilities are compounded by an institutional environment of common caregivers, shared living spaces, and a setting with a history of being under-resourced and ill-prepared to manage infection outbreaks. While COVID-19 related NH infections and mortality continue to increase nationwide, no one has reported on the impact of COVID-19 on NHs’ capacity to respond to the pandemic and to understand the impact of their response on clinical, functional, and psychosocial resident outcomes jointly. We are proposing a longitudinal mixed-methods study with the goal to develop knowledge and recommendations to improve US NHs’ ability to respond to respiratory HAI outbreaks. We have unique access to data recorded by the Quality Improvement Program for Missouri (QIPMO), a state-sponsored cooperative program. In March 2020, QIPMO began documenting NH COVID-19 infections and support provided to Missouri NHs. By June, there were over 2,400 documented QIPMO encounters providing us an unprecedented opportunity to study how NHs responded to COVID-19. In aim 1, we will use QIPMO data, state key informant interviews, and interviews with over 300 leaders and staff from 24 purposively sampled NHs to assess diverse NH pandemic responses, including enactment of federal guidance. In aim 2, using an interrupted time-series analysis, we will leverage statistical data from the Minimum Data Set (MDS) to determine the effects of the COVID-19 response on NH resident clinical, functional, and psychosocial outcomes. In aim 3, we will converge findings from aims 1 and 2 to identify relationships between contextual differences in NH responses and resident health outcomes to describe practices and strategies that either mitigated or contributed to adverse outcomes. Finally, in aim 4 we will convene an expert panel to review and recommend updates to current NH HAI guidelines and identify new practices and strategies to enhance NHs’ capacity to respond to infectious disease outbreaks including identifying implementation barriers, final dissemination plans and future intervention development. The likelihood that COVID-19 will become endemic and create needs for ongoing management is growing. Understanding how NHs’ responses influenced outcomes, including long-term resident effects, will inform future intervention development for US NHs to systematically prepare and manage infectious disease outbreaks. This study addresses the AHRQ priority to better prepare NHs for prevention and management, specifically high-risk respiratory HAI illnesses like COVID-19.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8928", "attributes": { "award_id": "1U01GH002366-01", "title": "GH21-001, Conducting Public Health Research in Thailand: Technical collaboration with the Ministry of Public Health (MOPH) in the Kingdom of Thailand", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2021-09-01", "end_date": "2026-08-31", "award_amount": 1568022, "principal_investigator": { "id": 24754, "first_name": "Kiattibhoom", "last_name": "Vongrachit", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1778, "ror": "", "name": "THAILAND MINISTRY OF PUBLIC HEALTH", "address": "", "city": "", "state": "", "zip": "", "country": "THAILAND", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1778, "ror": "", "name": "THAILAND MINISTRY OF PUBLIC HEALTH", "address": "", "city": "", "state": "", "zip": "", "country": "THAILAND", "approved": true }, "abstract": "The collaboration between CDC and Thailand MoPH have led to breakthroughs in research, improved programmatic practices and strengthened laboratory system. This is an umbrella Cooperative Agreement that will facilitate collaboration between Programs/Divisions within CDC Thailand and Thailand MoPH for the conduct of Public Health research on diseases of importance to both the United States and Thailand. The Permanent Secretary of Thailand MoPH is the Principle Investigator (PI) for this Research Cooperative Agreement and assigned Director of Strategy and Planning Division (SPD) to be business official will oversee project implementation and management through the project period respectively. The overall objectives of the MoPH CoAg project is to conduct epidemiologic, clinical field and laboratory research on important human infectious diseases, with emphasis on HV/AIDs, malaria, emerging and re- emerging infectious diseases, zoonotic diseases, , neglected tropical diseases, tuberculosis , influenza, coronaviruses and other diseases with pandemic potential, research on mobile and vulnerable populations including environmental health, chronic diseases, birth defects and developmental disabilities, maternal and child health, public health preparedness, biosafety and injury control and prevention. Results of this research project will be incorporated into operational system, surveillance, diseases control and prevention program in Thailand, including capacity building and sharing data to other agencies. In this application, the MoPH has proposed total of 12 projects, which comprised of 6 new projects and 7 continuation projects under programs as following:- 1. Coordinating Unit- CU1-MoPH The Ministry of Public Health Coordinating Unit(Continuation) 2. The Division of Global Health Protection (DGHP)- 2 projects: DGHP-AFINGS-BIDI (New) and DGHP- Sepsis-NGS (New) 3. Division of HIV/AIDS Prevention (DHAP)- 5 Projects: DHAP-COSERO (New), DHAP-HPTN083 (Continuation), DHAP-Main (Continuation), DHAP-TGW (Continuation), DHAP-ZOLI (Continuation) 4. Division of Global Migration and Quarantine (DGMQ)- 1 project: DGMQ-MNPC (New) 5. Non-Communicable Diseases (NCD)- 1 Project: FETP-NCD (New) 6. Influenza Program (FLU)- 2 projects: FLU-COVID-EPBI (Continuation), Flu-Serology (Continuation) Please see details of each project in attached file name-", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8930", "attributes": { "award_id": "1U18FD007493-01", "title": "COVID-19 - Vet-Lirn Network Capacity Building for SARS-CoV-2: -80 degree freezer andNanodrop", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24456, "first_name": "Olgica", "last_name": "Ceric", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-15", "end_date": "2022-08-31", "award_amount": 24603, "principal_investigator": { "id": 24756, "first_name": "Leyi", "last_name": "Wang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1040, "ror": "", "name": "UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1040, "ror": "", "name": "UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "The University of Illinois (UI) Veterinary Diagnostic Laboratory (VDL) is a full service, AAVLD accredited, all species, reference laboratory. UI VDL is a member of the VET-LIRN. Since last April, UI VDL has tested over one thousand of samples for SARS-CoV-2 and more than one hundred of samples of large cats in four different zoos were tested positive. These positive and negative samples are important for SARS-CoV-2 clinical and research related activities. New freezer and Nanodrop will significantly increase our storage and testing capacity for routine case investigation and surveillance coordinated by Vet-LIRN.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8936", "attributes": { "award_id": "1U01IP001158-01", "title": "IP21-002, Enhanced Surveillance Network for Enteric and Respiratory Viruses in Children: Assessing Disease Burden, Natural History, and Vaccine Effectiveness", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2021-09-01", "end_date": "2026-08-31", "award_amount": 1441647, "principal_investigator": { "id": 24763, "first_name": "Geoffrey Alan", "last_name": "Weinberg", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 464, "ror": "https://ror.org/022kthw22", "name": "University of Rochester", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 464, "ror": "https://ror.org/022kthw22", "name": "University of Rochester", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "(COMPONENTS A, B and C): Viral acute respiratory infections (ARI) and acute gastroenteritis (AGE) remain major causes of morbidity in children, making vaccine development and implementation a high public health priority. The overall goal of the CDC New Vaccine Surveillance Network (NVSN) is to establish a network of US institutions that develop and implement standard research protocols to answer important questions about the burden of disease and natural history of vaccine preventable diseases, specifically, those causing ARI and AGE. A second goal of population-based NVSN surveillance is to provide accurate estimates of vaccine effectiveness (VE) in preventing pediatric hospitalization or medical care visits. A third goal is the ability to rapidly pivot to study novel agents such as enterovirus-D68 (EV-D68) or SARS-CoV-2, and syndromes such as acute flaccid myelitis (AFM) and multisystem inflammatory syndrome in children (MIS-C). The proposed work (comprising Mandatory Core A, and Optional Components B and C) will enhance the NVSN site in Rochester, NY—one of 2 original members of the now 7-site network. For 20 years we have published important studies on the burden of disease and natural history of AGE due to rotavirus and norovirus, and ARI due to influenza, (RSV), and other viruses. These data helped inform AAP and ACIP on pediatric influenza and rotavirus vaccination, and palivizumab use for RSV prevention. Our specific aims are: Mandatory Core Component A: Perform prospective, population-based active surveillance for ARIs and AGEs in inpatient and ED settings as well as asymptomatic controls, for children 0-18 years. We will use molecular diagnostics for rotavirus, norovirus, influenza, RSV, PIV, EV-D68, SARS-CoV-2, and other viruses. We will assess VE for influenza, rotavirus, and future SARS-CoV-2 vaccines in preventing pediatric hospitalizations and ED visits. We will delineate the disease burden of ARI and AGE using our unique capture of virtually all pediatric hospitalizations and ED visits in our region. We will assess the impact of future vaccines and other immunoprophylaxis strategies. We will perform active surveillance and epidemiologic studies of acute flaccid myelitis (AFM) syndrome in children. Finally, we will perform and lead epidemiological, implementation and laboratory studies based on population-based NVSN surveillance. Optional Component B: Implement active prospective population-based ARI/AGE surveillance studies in children seeking medical care in outpatient practices, as the burden of ARI and AGE are likely high. Optional Component C: Investigate the incidence, spectrum of disease, and risk factors associated with SARS-CoV-2 MIS-C. Our proposed research will provide high impact information to develop sound policies for the prevention of pediatric vaccine-preventable diseases, and to improve the health of US children.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8941", "attributes": { "award_id": "1U18FD007495-01", "title": "'COVID-19' Incorporation of SARS-CoV-2 primers into a targeted NGS panel for surveillance use in cats", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24456, "first_name": "Olgica", "last_name": "Ceric", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-15", "end_date": "2022-08-31", "award_amount": 77500, "principal_investigator": { "id": 24771, "first_name": "Rebecca Penrose", "last_name": "Wilkes", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1139, "ror": "", "name": "PURDUE UNIVERSITY", "address": "", "city": "", "state": "IN", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1139, "ror": "", "name": "PURDUE UNIVERSITY", "address": "", "city": "", "state": "IN", "zip": "", "country": "United States", "approved": true }, "abstract": "SARS-CoV-2, the viral cause of COVID-19, has infected at least 94 pet cats in the United States, based on confirmed cases by the USDA. Many infections in cats are asymptomatic, and there are only a few ongoing surveillance studies in companion animals, so the number of cases in cats is likely higher. Cats are infected by SARS-CoV-2 from their human owners but have been shown experimentally to transmit the virus cat-to-cat. Once infected, at least experimentally, the virus quickly adapts in cats through genetic drift and positive selection at important residues within the spike protein, a protein used for cellular attachment. These adapted viruses are then spread to additional cats and maintained within the group. This can lead to accelerated fixation of potentially concerning variants for the human population if the virus is then able to re-infect humans. Additionally, cats may serve as a means for introducing variant viruses into wildlife populations based on their hunting behavior. Therefore, surveillance of cats for SARS-CoV-2 is warranted based on these considerations. Targeted surveillance should involve the interface of humans and animals, as this is most likely where these events will occur (infection of animals from humans with a potential of spillback to humans from animals). Pet cats in positive SARS-CoV-2 households are already known to be at risk for infection and should be included in a targeted active surveillance program involving domestic cats. Additionally, some cats show respiratory signs when infected with SARS-CoV-2, so the inclusion of SARS-CoV-2 testing, along with testing for the more likely pathogens that produce respiratory disease in cats, allows for additional passive surveillance. Cats submitted to diagnostic labs for necropsies can also easily be included in a surveillance program. To address surveillance needs, the Purdue Animal Disease Diagnostic Laboratory proposes to add SARS-CoV-2 primer sets to the targeted next-generation sequencing panel for detection of infectious diseases of dogs and cats. The amended panel will be validated for the detection of SARS-CoV-2 by using a set of sequenced positive samples, which contains all the current SARS-CoV-2 variants of interest and concern, as defined by the CDC. Additionally, nasal and oropharyngeal swabs will be collected from cats for surveillance testing based on the above criteria. These samples will be tested by both an approved RT-PCR for SARS-CoV-2 and the targeted NGS panel to determine the diagnostic sensitivity/specificity of the panel for detection of SARS-CoV-2. Additionally, any positive samples we obtain from the cats will be sequenced to evaluate variants associated with infection. Addition of this virus to commonly used panels for infectious diseases will allow for continued passive surveillance without the need to specifically request and obtain approval for the testing. This should enhance our detection of this virus in cats, potentially preventing the unwanted introduction or spread into new populations.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8942", "attributes": { "award_id": "1U01IP001152-01", "title": "IP21-002, New Vaccine Surveillance Network", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2021-09-01", "end_date": "2026-08-31", "award_amount": 1402123, "principal_investigator": { "id": 24772, "first_name": "Marian G", "last_name": "Michaels", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 848, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 24773, "first_name": "John V.", "last_name": "Williams", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 848, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "(For Components A, B, and C). Acute gastroenteritis (AGE) and acute respiratory illness (ARI) are leading causes of childhood disease, accounting for a large proportion of hospitalizations, Emergency Department (ED) visits, and outpatient visits annually in the US. These illnesses are caused by diverse pathogens, including influenza, respiratory syncytial virus, human metapneumovirus, parainfluenza viruses, rhinovirus, enterovirus (EV), coronavirus including SARS-CoV-2, adenovirus, rotavirus, norovirus, astrovirus, and sapovirus. Moreover, some of these viruses are associated with other emerging childhood syndromes, including acute flaccid myelitis (AFM) associated with EV, and multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2. Thus, viral AGE and ARI are of major public health importance, and result in serious long-term consequences for some children. There are few or no effective antivirals for these viruses and vaccination is the most promising intervention. Our goals are to conduct active, prospective population-based surveillance for AGE and ARI; to define the burden of vaccine-preventable diseases; describe the clinical features, natural history, and population dynamics; and establish vaccine effectiveness (VE) of licensed and impending vaccines and monitor VE over time. The New Vaccine Surveillance Network (NVSN) will facilitate these goals. We propose four Specific Aims: Aim 1: to conduct prospective active surveillance for AGE due to norovirus, rotavirus, and other enteric viruses among children seeking healthcare in ED, inpatient, and outpatient settings. (Component A, Mandatory Component 1; Optional Component B) Aim 2: to conduct prospective active surveillance for ARI due to respiratory viruses in these settings. (Component A, Mandatory Component 1; Optional Component B) Aim 3: to conduct prospective active surveillance for AFM syndrome in these settings. (Component A, Mandatory Component 2) Aim 4: to conduct prospective active surveillance for MIS-C. (Optional Component C) The Pittsburgh site has extensive experience with pediatric clinical research, including as a top enrolling NVSN site in the current NVSN cycle. UPMC Children’s Hospital of Pittsburgh (CHP) has a catchment area of >5.5 million people and admits >95% of hospitalized children in the surrounding county of >1.2 million. Thus, the environment is excellent for population-based research. The experienced investigative team includes experts from pediatric infectious diseases, critical care, rheumatology, and cardiology. The data and samples collected in this project will facilitate the capacity to calculate VE for multiple licensed and pending vaccines. The results of this project will inform best practices for diagnosis and treatment, guide vaccine recommendations, and determine public health interventions to prevent viral illness-related medical visits among children.", "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 1384, "pages": 1442, "count": 14420 } } }